Hepatic cyst liver cyst post-procedural cyst infection spontaneous hepatic cyst infection
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All patients who are diagnosed with a dominant hepatic cyst and have an indication for aspiration sclerotherapy are suitable for inclusion in this study. The indication for aspiration sclerotherapy is made upon diagnosis of a symptomatic, solitary or dominant simple hepatic cyst, exceeding 5 cm.;In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age >=18 years - Indication for aspiration and sclerotherapy - Providing informed consent
Exclusion criteria
Exclusion criteria: 1. Presence of an arteriovenous fistula, history of mastectomy or lymph node dissection at both extremities 2. Signs of phlebitis, defined as localized skin redness and swelling, at both extremities 3. History of cephalosporin and/or penicillin allergy consisting of IgE-mediated reactions as anaphylaxis, angioedema, urticaria. 4. Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is hepatic cyst penetration of cefazolin defined as the ratio (%) of cyst aspirate concentration (µg/ml) to serum concentration (µg/ml) of cefazolin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters are location and volume of the aspirated hepatic cyst, cyst fluid and serum parameters, and development of clinical signs indicating aspiration sclerotherapy-induced cyst infection. | — |
Countries
Netherlands
Outcome results
None listed